Antidepressants in Pregnancy: Which SSRIs Are Safest?

TL;DR

• Depression in pregnancy is common (10–20% of pregnant individuals) and undertreated; untreated depression itself poses risks to mother and fetus.
• Sertraline is generally considered the first-line SSRI in pregnancy based on the largest body of reassuring reproductive safety data (ACOG, MotherToBaby).
• No SSRI has been proven to cause major structural birth defects at a clinically meaningful rate, though paroxetine carries a specific FDA warning and is typically avoided.
• All SSRIs carry a small absolute risk of persistent pulmonary hypertension of the newborn (PPHN) and neonatal adaptation syndrome — but the absolute risk remains low.
• The decision to start, continue, or stop an antidepressant in pregnancy should always be individualized with the prescriber, weighing the real risks of untreated illness against medication exposure.

Why Depression in Pregnancy Matters

Perinatal depression — depression occurring during pregnancy or in the first year postpartum — affects an estimated 10–20% of pregnant individuals worldwide. Despite its prevalence, it remains substantially underdiagnosed and undertreated. The consequences of leaving moderate-to-severe depression untreated during pregnancy are not trivial: poor prenatal care adherence, inadequate nutrition, increased substance use, preeclampsia, preterm birth, low birth weight, impaired maternal–infant bonding, and elevated risk of postpartum depression and self-harm.

ACOG Committee Opinion 757 (reaffirmed 2020) is explicit on this point: the risks of untreated or inadequately treated depression frequently outweigh the potential risks of antidepressant therapy. The American College of Obstetricians and Gynecologists recommends that clinicians screen all pregnant and postpartum patients for depression using a validated tool (such as the Edinburgh Postnatal Depression Scale) and that pharmacotherapy should not be reflexively discontinued simply because a patient becomes pregnant.

This article examines the evidence behind which antidepressants are safe in pregnancy, compares the reproductive safety profiles of the most commonly prescribed agents, and provides practical guidance grounded in current guidelines.

How SSRIs Work — A Brief Pharmacological Overview

Selective serotonin reuptake inhibitors (SSRIs) block the reuptake of serotonin (5-HT) at the presynaptic neuron, increasing serotonergic transmission in the synaptic cleft. This mechanism underlies their efficacy in major depressive disorder, generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder — all of which may coexist with or worsen during pregnancy due to hormonal and psychosocial changes.

All SSRIs cross the placenta, and fetal serum concentrations vary by agent. The ratio of umbilical cord blood concentration to maternal serum concentration ranges from roughly 0.29 for sertraline to 0.70–0.86 for fluoxetine and citalopram. This pharmacokinetic detail partially informs safety discussions, though cord blood levels alone do not determine clinical risk.

Venlafaxine, a serotonin–norepinephrine reuptake inhibitor (SNRI), is included in this review because it is frequently prescribed when SSRIs provide insufficient response, and pregnancy-specific data are now sufficient for meaningful comparison.

Comparing SSRI Safety Profiles in Pregnancy

The four agents most commonly evaluated in pregnancy are sertraline (Zoloft), fluoxetine (Prozac), citalopram (Celexa), and escitalopram (Lexapro), along with the SNRI venlafaxine (Effexor). Paroxetine (Paxil) is intentionally excluded from first-line recommendations because of an FDA Class D designation based on early data suggesting increased risk of cardiac malformations — a risk not consistently replicated in later studies but sufficient to warrant preferring alternatives.

The following table summarizes the key reproductive safety data for each agent.

SSRI and SNRI Pregnancy Safety Comparison

Key takeaway: Sertraline has the largest evidence base, the lowest placental transfer ratio, and is the agent most frequently cited by ACOG and MotherToBaby as a preferred first-line option in pregnancy and lactation.

First-Trimester Exposure: What the Data Actually Show

The first trimester is the period of organogenesis — the window during which structural birth defects are most likely to occur if a teratogenic exposure is present. For SSRIs as a class, the data are broadly reassuring.

Large registry and cohort studies (including data from the Swedish Medical Birth Register, the U.S. National Birth Defects Prevention Study, and the Quebec Pregnancy Cohort) have generally found:

• No clinically significant increase in the overall rate of major congenital malformations above the population baseline of approximately 2–4%.
• Some individual studies have reported statistically significant associations between specific SSRIs and specific malformations (e.g., fluoxetine and right ventricular outflow tract defects, or paroxetine and ventricular septal defects). However, when these are examined across the full body of evidence, the absolute risk increases — if real — are very small (on the order of 1–2 additional cases per 1,000 exposures), and confounding by indication (depression itself, comorbid conditions, concurrent medication use) remains difficult to fully eliminate.
• A 2015 Cochrane-protocol systematic review and a 2019 meta-analysis published in JAMA Psychiatry both concluded that the association between SSRI use and congenital heart defects is weak, inconsistent across agents, and of uncertain clinical significance when absolute risk is considered.

Sertraline has the most consistently reassuring first-trimester data. Multiple large cohort studies — including Huybrechts et al. (2014) in the New England Journal of Medicine, which examined over 64,000 SSRI-exposed pregnancies — found no significant increase in cardiac malformations with sertraline after adjusting for confounders.

Fluoxetine has occasionally shown a small signal for cardiac defects in some registries, but this has not been replicated in the largest and most methodologically rigorous studies. Its long half-life (and active metabolite norfluoxetine, half-life 4–16 days) means the fetus has sustained exposure even after the mother discontinues the drug — a consideration for planned pregnancies.

Persistent Pulmonary Hypertension of the Newborn (PPHN)

PPHN is a serious neonatal condition in which pulmonary vascular resistance remains elevated after birth, causing hypoxemia. In 2006, the FDA issued a Public Health Advisory linking late-pregnancy SSRI exposure to PPHN, based on a case-control study by Chambers et al. that reported an adjusted odds ratio of approximately 6.

Since then, the evidence has been extensively re-examined:

• The baseline incidence of PPHN is approximately 1–2 per 1,000 live births.
• The most rigorous studies (including Huybrechts et al., 2015, BMJ) estimate that SSRI exposure after 20 weeks of gestation is associated with an adjusted risk of roughly 3 per 1,000 — an absolute increase of approximately 1 additional case per 1,000 exposed pregnancies.
• The FDA updated its safety communication in 2011, stating that the original findings were "premature" and that the evidence does not conclusively establish or exclude a causal relationship between SSRI use and PPHN.

Clinically, this means: the absolute risk of PPHN with SSRI use is low. For a patient with moderate-to-severe depression who is stable on an SSRI, the risk of PPHN alone does not generally justify discontinuation. Neonatology teams should be aware of maternal SSRI use at delivery so that appropriate monitoring is in place.

Neonatal Adaptation Syndrome

Neonatal adaptation syndrome (NAS, sometimes called "poor neonatal adaptation" or "neonatal withdrawal") occurs in an estimated 15–30% of neonates exposed to SSRIs or SNRIs in the third trimester. Symptoms typically appear within the first 24–48 hours of life and may include:

• Jitteriness, tremor, increased muscle tone
• Irritability, excessive crying
• Feeding difficulties
• Respiratory distress (tachypnea, rarely requiring supplemental oxygen)
• Sleep disturbance
• In rare cases, seizures

NAS is almost always mild and self-limiting, resolving within 2–7 days without pharmacological intervention. It is not a true "withdrawal" in the pharmacological sense — the mechanism likely involves a combination of serotonergic overstimulation, mild withdrawal, and direct drug effects.

Venlafaxine may carry a somewhat higher incidence and severity of NAS compared to SSRIs, potentially due to its dual mechanism and short half-life (leading to more abrupt neonatal drug clearance).

Management is supportive: skin-to-skin contact, demand feeding, minimizing stimulation, and monitoring. The Academy of Breastfeeding Medicine and NICE recommend that breastfeeding be encouraged, as it may mitigate NAS symptoms.

Red flag: NAS requiring NICU admission, respiratory support, or lasting beyond 7 days should prompt evaluation for alternative diagnoses.

Dosing Considerations in Pregnancy

Pregnancy induces substantial pharmacokinetic changes — increased plasma volume, increased hepatic blood flow, enhanced CYP enzyme activity (particularly CYP2D6 and CYP3A4), and increased renal clearance — that can reduce serum drug concentrations. Many patients require dose increases in the second and third trimesters to maintain therapeutic efficacy.

SSRI/SNRI Dosing Reference in Pregnancy

Practical guidance:

• Do not abruptly discontinue SSRIs in the third trimester to "avoid neonatal effects" — this strategy is not supported by evidence and exposes the mother to relapse risk during the most vulnerable peripartum period.
• Therapeutic drug monitoring is not routinely available for SSRIs but may be useful in refractory cases or when adherence is uncertain.
• After delivery, hepatic metabolism returns to pre-pregnancy levels over 2–4 weeks; if doses were increased during pregnancy, consider gradual dose reduction postpartum to avoid supratherapeutic levels.

Side Effects and Monitoring

SSRI side effects in pregnancy are generally consistent with those observed in non-pregnant adults. However, certain effects warrant heightened attention:

• Nausea and vomiting: May compound pregnancy-related nausea, particularly in the first trimester. Taking the medication with food or at bedtime may help.
• Weight changes: SSRIs can cause modest weight gain or loss; monitor nutritional adequacy.
• Sexual dysfunction: May be less of a concern for some patients during pregnancy but should still be discussed.
• Hyponatremia (SIADH): Rare but can occur; more common in older adults but occasionally reported in pregnancy.
• Bleeding risk: SSRIs impair platelet aggregation. Consider this in the peripartum period, particularly if the patient requires neuraxial anesthesia or has other bleeding risk factors.
• QTc prolongation: Relevant primarily for citalopram at higher doses (>40 mg/day); obtain baseline ECG if clinically indicated.

Monitoring recommendations:

• Standardized depression screening at each prenatal visit (Edinburgh Postnatal Depression Scale or PHQ-9)
• Assessment for suicidal ideation, particularly in the first weeks after initiation or dose change
• Blood pressure monitoring for patients on venlafaxine
• Neonatal observation for at least 24–48 hours after delivery if the mother was taking an SSRI or SNRI in the third trimester

Contraindications, Interactions, and Agents to Avoid

Agents to Avoid in Pregnancy

Key Drug Interactions

• St. John's wort: Induces CYP3A4; reduces SSRI efficacy and poses photosensitivity risk. Should not be combined.
• NSAIDs: Additive bleeding risk with SSRIs. Paracetamol (acetaminophen) is preferred for pain management in pregnancy.
• Ondansetron (Zofran): Commonly used for hyperemesis; potential additive QTc prolongation risk when combined with citalopram. Use alternative antiemetics when possible.
• Triptans: Serotonin syndrome risk when combined with SSRIs/SNRIs, though clinical significance is debated.
• Lithium and lamotrigine: May be co-prescribed for bipolar depression; require specialist perinatal psychiatry input and therapeutic drug monitoring.

Special Populations

Breastfeeding

LactMed — the NIH's Drugs and Lactation Database — provides agent-specific guidance:

• Sertraline is the preferred SSRI during breastfeeding. Infant serum levels are typically undetectable or very low. No adverse effects on infant development have been demonstrated in follow-up studies.
• Fluoxetine is compatible with breastfeeding but produces higher infant serum levels than sertraline due to its long half-life and active metabolite. Occasional reports of infant irritability and poor feeding exist, though large-scale adverse effects have not been documented.
• Citalopram/escitalopram are compatible with breastfeeding; infant exposure levels are intermediate.
• Venlafaxine is compatible with breastfeeding but carries a somewhat higher relative infant dose (~6–8% of the maternal weight-adjusted dose). Monitor infants for sedation and adequate weight gain.

Adolescent Pregnancy

Adolescents face a heightened risk of perinatal depression and are less likely to access mental health services. SSRI safety data in adolescent pregnancy are limited but are generally extrapolated from adult data. Fluoxetine is the only SSRI with robust evidence for efficacy in adolescent depression (non-pregnant), and the FDA black box warning regarding suicidality in individuals under 25 remains relevant. Close monitoring is essential.

Patients with Comorbid Anxiety Disorders

Anxiety disorders frequently co-occur with depression in pregnancy. SSRIs are effective for both conditions. Sertraline has good evidence for panic disorder and social anxiety disorder in addition to major depression, making it a practical choice for patients with comorbid presentations. Benzodiazepines should be used cautiously and at the lowest effective dose if needed adjunctively, due to neonatal sedation and "floppy infant" risk.

Patients Planning Pregnancy

For patients with stable, well-controlled depression on an SSRI who are planning pregnancy, ACOG does not recommend preconception switching solely to "de-risk" the pregnancy — switching agents may cause relapse during the transition, and the destination drug may not be as effective. If the patient is on paroxetine, however, a preconception switch to sertraline or another preferred agent is reasonable.

Red Flags — When to Seek Immediate Medical Attention

Patients and clinicians should be aware of the following urgent scenarios:

• Suicidal ideation or self-harm at any point during pregnancy or postpartum — this is a psychiatric emergency requiring immediate evaluation.
• Psychotic features (hallucinations, delusions, disorganized behavior) — may indicate postpartum psychosis, which requires inpatient treatment.
• Serotonin syndrome symptoms (agitation, hyperthermia, clonus, diaphoresis, tachycardia) — particularly if the patient is on multiple serotonergic agents.
• Severe NAS in the newborn — respiratory distress, seizures, inability to feed, or symptoms lasting beyond 7 days.
• Abrupt discontinuation symptoms in the mother — dizziness, paresthesias ("brain zaps"), irritability, insomnia, nausea — should prompt medical guidance for reinstatement or gradual taper rather than continued abrupt cessation.

Frequently Asked Questions

Q: Will taking an SSRI during pregnancy harm my baby? A: The evidence from large cohort studies indicates that SSRIs — particularly sertraline — do not cause major birth defects at a rate meaningfully above the general population baseline of 2–4%. All medications carry some theoretical risk, but for moderate-to-severe depression, the risks of untreated illness typically outweigh the small, often unconfirmed medication risks.

Q: Is sertraline the safest antidepressant in pregnancy? A: Sertraline is the most extensively studied SSRI in pregnancy and has the most consistently reassuring safety data, the lowest placental transfer ratio, and the best lactation safety profile. It is often cited as first-line by ACOG and MotherToBaby. That said, "safest" depends on individual response — an SSRI that does not treat the mother's depression effectively is not a safe choice regardless of its reproductive profile.

Q: Should I stop my antidepressant when I find out I'm pregnant? A: Do not stop abruptly. Contact your prescriber as soon as possible. Abrupt discontinuation increases the risk of relapse, discontinuation syndrome, and adverse pregnancy outcomes related to untreated depression. The decision to continue, adjust, or taper should be individualized.

Q: Can SSRIs cause autism in my child? A: Several early studies suggested an association between prenatal SSRI exposure and autism spectrum disorder. However, more rigorous studies that controlled for maternal psychiatric diagnosis found that the association largely disappeared — suggesting it was the underlying depression and its genetic correlates, not the medication, driving the association. Current consensus from ACOG and the Society for Maternal-Fetal Medicine is that SSRIs have not been proven to cause autism.

Q: Is it safe to breastfeed while taking an antidepressant? A: Yes, for most commonly prescribed SSRIs. Sertraline is preferred because infant serum levels are typically undetectable. LactMed provides detailed, regularly updated drug-specific information. The benefits of breastfeeding — for both maternal mental health and infant health — generally support continuing antidepressant therapy rather than discontinuing it.

Q: What about natural alternatives like St. John's wort or omega-3 fatty acids? A: St. John's wort is not recommended in pregnancy — it is a potent CYP inducer, interacts with multiple medications, and has limited safety data in pregnancy. Omega-3 supplementation (particularly EPA) has modest evidence for adjunctive benefit in depression but is not a substitute for pharmacotherapy in moderate-to-severe disease. Psychotherapy, particularly cognitive behavioral therapy (CBT) and interpersonal therapy (IPT), has strong evidence as monotherapy for mild depression or as adjunctive treatment alongside medication.

Q: Will my baby have withdrawal symptoms after birth? A: Approximately 15–30% of neonates exposed to SSRIs in the third trimester may exhibit neonatal adaptation syndrome — jitteriness, irritability, feeding difficulties, and occasionally respiratory symptoms. This is typically mild, self-limiting, and resolves within 2–7 days. It should not be a reason to discontinue an effective antidepressant in late pregnancy.

Q: Can my partner's SSRI use affect conception or pregnancy? A: SSRI use in male partners has been studied to a limited extent. Some data suggest SSRIs may affect sperm motility and DNA fragmentation, but the clinical significance of these findings for fertility and pregnancy outcomes is uncertain. There is no evidence that paternal SSRI use causes birth defects.

References

1. ACOG. Committee Opinion No. 757: Screening for Perinatal Depression. Obstet Gynecol. 2018;132(5):e208–e212. acog.org/clinical/clinical-guidance/committee-opinion/articles/2018/11/screening-for-perinatal-depression

2. Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014;370(25):2397–2407. PMID: 24941178

3. Huybrechts KF, Bateman BT, Palmsten K, et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA. 2015;313(21):2142–2151. PMID: 26034955

4. National Library of Medicine. LactMed: Drugs and Lactation Database — Sertraline. ncbi.nlm.nih.gov/books/NBK501186/

5. MotherToBaby. Sertraline (Zoloft) Fact Sheet. Organization of Teratology Information Specialists. mothertobaby.org/fact-sheets/sertraline-zoloft-pregnancy

6. NICE. Antenatal and postnatal mental health: clinical management and service guidance. Guideline CG192. 2014 (updated 2020). nice.org.uk/guidance/cg192

7. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Clin Psychiatry. 2013;74(4):e309–e320. PMID: 23656856

8. FDA. FDA Drug Safety Communication: Selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies. 2011. fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-selective-serotonin-reuptake-inhibitor-ssri-antidepressant-use-during

9. Sujan AC, Rickert ME, Öberg AS, et al. Associations of maternal antidepressant use during the first trimester of pregnancy with preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit/hyperactivity disorder in offspring. JAMA. 2017;317(15):1553–1562. PMID: 28418479

10. Byatt N, Deligiannidis KM, Arnason M, et al. Massachusetts Child Psychiatry Access Project for Moms: utilization and quality assessment. Obstet Gynecol. 2018;132(2):345–353. PMID: 29995725

About the Author

Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with over 15 years of experience spanning hospital pharmacy, ambulatory care, and drug information services. He holds a Doctor of Pharmacy degree and has served as a clinical educator and formulary reviewer. Dr. Ozarchuk writes for PillsCard.com with a focus on translating complex pharmacological evidence into clear, practical guidance for patients and healthcare providers. His work emphasizes evidence-based medicine, guideline-concordant practice, and transparent communication of both benefits and risks.

Medical Disclaimer

This article is provided for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. The content reflects published evidence and clinical guidelines available at the time of writing but may not capture the most recent updates. Do not start, stop, or change any medication — including antidepressants — without consulting your physician, obstetrician, or qualified healthcare provider. Individual clinical circumstances vary, and treatment decisions should always be made collaboratively with a licensed prescriber who has full knowledge of your medical history. PillsCard.com and the author assume no liability for actions taken based on the information presented herein. If you are experiencing a mental health crisis, contact your local emergency services or a crisis helpline immediately.